Predicting a combined treatment outcome in chronic Schizophrenia: The role of demographics, symptomatology, functioning and subjective well-being

D. Naber; S. Kollack-Walker; J. Chen; V. L. Stauffer; B. J. Kinon; M. Case; H. Ascher-Svanum; S. Kapur; J. M. Kane

doi:10.1055/s-0032-1331703

Predicting a combined treatment outcome in chronic Schizophrenia: The role of demographics, symptomatology, functioning and subjective well-being

D. Naber^*, S. Kollack-Walker, J. Chen, V. L. Stauffer, B. J. Kinon, M. Case, H. Ascher-Svanum, S. Kapur, J. M. Kane

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Objectives: The aim of this study was to determine what variables predict a 'combined treatment outcome' (COMBOUT) in patients with chronic schizophrenia. Methods: This analysis (n=522) was based on a randomized, double-blind, flexible-dose, 12-week study that enrolled chronically-ill patients diagnosed with schizophrenia or a related disorder. COMBOUT was assessed using the PANSS for symptoms, CGI-S for overall clinical status, MADRS for depressive symptoms, QLS for functioning/QOL, and SWN-K for subjective well-being. Possible predictors included demographics as well as baseline scores (Model I), and early change (week 2) scores (Model II). Results: Model I: significantly better outcome (higher COMBOUT score) was observed in patients with lower MADRS (T= - 6.36; p

Original language	English
Pages (from-to)	114-119
Number of pages	6
Journal	Pharmacopsychiatry
Volume	46
Issue number	3
DOIs	https://doi.org/10.1055/s-0032-1331703
Publication status	Published - 2013

Keywords

antipsychotics
olanzapine
prediction
risperidone
schizophrenia

Access to Document

10.1055/s-0032-1331703

Cite this

@article{85e87c4b81ec4d59880b9fbd0093e9c8,

title = "Predicting a combined treatment outcome in chronic Schizophrenia: The role of demographics, symptomatology, functioning and subjective well-being",

abstract = "Objectives: The aim of this study was to determine what variables predict a 'combined treatment outcome' (COMBOUT) in patients with chronic schizophrenia. Methods: This analysis (n=522) was based on a randomized, double-blind, flexible-dose, 12-week study that enrolled chronically-ill patients diagnosed with schizophrenia or a related disorder. COMBOUT was assessed using the PANSS for symptoms, CGI-S for overall clinical status, MADRS for depressive symptoms, QLS for functioning/QOL, and SWN-K for subjective well-being. Possible predictors included demographics as well as baseline scores (Model I), and early change (week 2) scores (Model II). Results: Model I: significantly better outcome (higher COMBOUT score) was observed in patients with lower MADRS (T= - 6.36; p",

keywords = "antipsychotics, olanzapine, prediction, risperidone, schizophrenia",

author = "D. Naber and S. Kollack-Walker and J. Chen and Stauffer, {V. L.} and Kinon, {B. J.} and M. Case and H. Ascher-Svanum and S. Kapur and Kane, {J. M.}",

year = "2013",

doi = "10.1055/s-0032-1331703",

language = "English",

volume = "46",

pages = "114--119",

journal = "Pharmacopsychiatry",

issn = "0176-3679",

publisher = "Georg Thieme Verlag",

number = "3",

}

TY - JOUR

T1 - Predicting a combined treatment outcome in chronic Schizophrenia

T2 - The role of demographics, symptomatology, functioning and subjective well-being

AU - Naber, D.

AU - Kollack-Walker, S.

AU - Chen, J.

AU - Stauffer, V. L.

AU - Kinon, B. J.

AU - Case, M.

AU - Ascher-Svanum, H.

AU - Kapur, S.

AU - Kane, J. M.

PY - 2013

Y1 - 2013

N2 - Objectives: The aim of this study was to determine what variables predict a 'combined treatment outcome' (COMBOUT) in patients with chronic schizophrenia. Methods: This analysis (n=522) was based on a randomized, double-blind, flexible-dose, 12-week study that enrolled chronically-ill patients diagnosed with schizophrenia or a related disorder. COMBOUT was assessed using the PANSS for symptoms, CGI-S for overall clinical status, MADRS for depressive symptoms, QLS for functioning/QOL, and SWN-K for subjective well-being. Possible predictors included demographics as well as baseline scores (Model I), and early change (week 2) scores (Model II). Results: Model I: significantly better outcome (higher COMBOUT score) was observed in patients with lower MADRS (T= - 6.36; p

AB - Objectives: The aim of this study was to determine what variables predict a 'combined treatment outcome' (COMBOUT) in patients with chronic schizophrenia. Methods: This analysis (n=522) was based on a randomized, double-blind, flexible-dose, 12-week study that enrolled chronically-ill patients diagnosed with schizophrenia or a related disorder. COMBOUT was assessed using the PANSS for symptoms, CGI-S for overall clinical status, MADRS for depressive symptoms, QLS for functioning/QOL, and SWN-K for subjective well-being. Possible predictors included demographics as well as baseline scores (Model I), and early change (week 2) scores (Model II). Results: Model I: significantly better outcome (higher COMBOUT score) was observed in patients with lower MADRS (T= - 6.36; p

KW - antipsychotics

KW - olanzapine

KW - prediction

KW - risperidone

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84878111318&partnerID=8YFLogxK

U2 - 10.1055/s-0032-1331703

DO - 10.1055/s-0032-1331703

M3 - Article

C2 - 23293013

AN - SCOPUS:84878111318

SN - 0176-3679

VL - 46

SP - 114

EP - 119

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

IS - 3

ER -

Predicting a combined treatment outcome in chronic Schizophrenia: The role of demographics, symptomatology, functioning and subjective well-being

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this